Video Experimental Relacionado

Updated: Jul 25, 2026

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

Modificación del NADH del objetivo de la isoniazida (InhA) de Mycobacterium tuberculosis

D A Rozwarski¹, G A Grant, D H Barton

¹Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.

Science (New York, N.Y.)

|January 24, 1998

Resumen

La isoniazida, un medicamento preferido para la tuberculosis, actúa al unirse covalentemente a la enzima InhA. Este mecanismo detallado aclara cómo la isoniazida inhibe la biosíntesis del ácido micólico en Mycobacterium tuberculosis.

Área de la Ciencia:

La bioquímica es la bioquímica.
Microbiología Microbiología.
Descubrimiento de Drogas Descubrimiento de Drogas

Sus antecedentes:

La isoniazida es un medicamento primario para el tratamiento de la tuberculosis causada por Mycobacterium tuberculosis.
El mecanismo preciso de acción de la isoniazida contra la enzima InhA no ha estado claro desde hace más de 40 años.
InhA es crucial para la biosíntesis del ácido micólico, un componente clave de la pared celular de la tuberculosis.

Objetivo del estudio:

Para aclarar el mecanismo molecular detallado de la acción de la isoniazida contra InhA.
Para entender cómo la isoniazida inhibe la biosíntesis del ácido micólico esencial en el Mycobacterium tuberculosis.

Principales métodos:

Se empleó cristalografía de rayos X para visualizar las interacciones fármaco-enzima.
Se utilizó la espectrometría de masas para identificar modificaciones moleculares y eventos de unión.

Principales resultados:

El estudio revela que la forma activada de la isoniazida se une covalentemente al dinucleótido de nicotinamida adenina (NAD).
Esta unión ocurre dentro del sitio activo de la enzima InhA.
La unión covalente inhibe la función de InhA en la síntesis del ácido micólico.

Conclusiones:

El modo preciso de acción de la isoniazida implica la modificación covalente de NAD dentro del sitio activo de InhA.
Este hallazgo proporciona una base molecular para la eficacia de la isoniazida contra la tuberculosis.
La comprensión de este mecanismo puede ayudar en el desarrollo de nuevos agentes antituberculosos.

Más Videos Relacionados

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Videos de Conceptos Relacionados

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...